Clinical reference Biomarker Directory
Back to directory

Brain natriuretic peptide

Established

BNP/NT-proBNP is the primary blood marker for diagnosing and staging heart failure.

Also known as BNP NT-proBNP B-type natriuretic peptide
In plain language

BNP is a heart hormone that rises when the heart is under strain, helping doctors diagnose and grade heart failure. The "normal" cutoff isn't one-size-fits-all — it should probably be adjusted for age, and it reads falsely low in patients with obesity.

Biomarker & context

Brain natriuretic peptide (BNP) and its precursor fragment NT-proBNP are hormones released by the heart ventricles in response to wall stress, serving as the primary blood biomarkers for diagnosing and staging heart failure.

What it indicates

Elevated BNP/NT-proBNP supports a heart failure diagnosis in a patient with dyspnea, with higher levels correlating with disease severity; levels are also used for risk stratification and monitoring treatment response.

Diagnosis & clinical testing

Guideline cutoffs vary: NICE recommends >400 ng/L (NT-proBNP) and ESC recommends >125 ng/L for outpatient workup. Current research (2024-2025) argues for age-adjusted thresholds, since levels naturally rise with age, and levels run lower in patients with obesity, which can mask heart failure under a universal cutoff.

Guiding treatment

BNP/NT-proBNP guides decisions about hospitalization/discharge and identifies patients at higher risk for cardiovascular events; levels are also used to differentiate cardiac from non-cardiac causes of shortness of breath in the emergency department.

Clinical significance

Widely used cutoffs may need age- and BMI-adjustment for optimal accuracy per current research.

References
  1. Berthelot, E., et al. (2024). Setting the optimal threshold of NT-proBNP and BNP for the diagnosis of heart failure in patients over 75 years. PMC.
  2. JACC. (2021). NT-proBNP for Risk Prediction in Heart Failure: Optimal Cutoffs Across BMI Categories.